Back to all Companies

PD Neurotechnology

Visit Website
Healthcare & Life SciencesWearables, Devices and Hardware
Year Founded
Year Selected
London, United Kingdom
Team Size


A sophisticated expert system for patients with Parkinson’s disease.

PD Neurotechnology is a medical technology company that was founded in 2016 in the UK by a team of experienced professionals with a strong background in the healthcare industry. The company's main mission is to provide an innovative solution for continuous monitoring of Parkinson's disease symptoms, which was previously not possible with traditional monitoring methods. PD Neurotechnology's wearable non-invasive device facilitates continuous monitoring, tracing, recording, and processing of a variety of symptoms frequently presented in the disease, working in conjunction with a mobile app that facilitates patient-doctor interaction. PD Neurotechnology is solving the problem of the inability to continuously monitor Parkinson's disease symptoms with traditional monitoring methods. Their device provides a non-invasive and easy-to-use solution that enables healthcare providers to make better clinical decisions and promote better patient-physician interaction. PD Neurotechnology's business model is centered around making their monitoring device and accompanying platform available to healthcare providers and institutions. The company stands out in its commitment to innovation and providing cutting-edge solutions to improve patient care in the healthcare industry. The company’s Greek branch is located in Athens, while its research, development and production facilities are in Ioannina, Greece, while the company also operates in multiple locations around the world.


What excites us about PD Neurotechnology is their innovative approach to solving a critical problem in the healthcare industry, their commitment to improving patient care, and their ability to disrupt the medical device sector. Their wearable non-invasive device and platform provide an easy-to-use and non-intrusive solution that allows for continuous monitoring and tracking of Parkinson's disease symptoms, leading to better clinical decision-making and patient care.


investor logo
ScaleUp Program

Relevant Resources

See All

Endeavor Scale-up Program: 2nd Cohort

Jan 10, 2021